Madrigal Pharmaceuticals (MDGL) EBIAT (2019 - 2025)
Madrigal Pharmaceuticals (MDGL) has disclosed EBIAT for 13 consecutive years, with -$58.6 million as the latest value for Q4 2025.
- On a quarterly basis, EBIAT rose 1.39% to -$58.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$288.3 million, a 38.12% increase, with the full-year FY2025 number at -$288.3 million, up 38.12% from a year prior.
- EBIAT was -$58.6 million for Q4 2025 at Madrigal Pharmaceuticals, up from -$114.2 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of -$42.3 million in Q2 2025 to a low of -$152.0 million in Q2 2024.
- A 5-year average of -$83.3 million and a median of -$75.1 million in 2023 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 91.87% in 2024, then soared 72.18% in 2025.
- Madrigal Pharmaceuticals' EBIAT stood at -$64.5 million in 2021, then crashed by 33.08% to -$85.9 million in 2022, then plummeted by 30.64% to -$112.2 million in 2023, then surged by 47.06% to -$59.4 million in 2024, then rose by 1.39% to -$58.6 million in 2025.
- Per Business Quant, the three most recent readings for MDGL's EBIAT are -$58.6 million (Q4 2025), -$114.2 million (Q3 2025), and -$42.3 million (Q2 2025).